Brief: Bergenbio's Bemcentinib Meets Efficacy Endpoint In Bergamo Phase II Trial

Oncoinvent ASA

18/08/2020 06:10

Aug 18 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO'S BEMCENTINIB MEETS EFFICACY ENDPOINT IN BERGAMO PHASE II TRIAL
    * PRIMARY ENDPOINT OF OVERALL RESPONSE RATE HAS BEEN MET IN BERGAMO PHASE II TRIAL
INVESTIGATING
BERGENBIO'S SELECTIVE AXL INHIBITOR BEMCENTINIB IN PATIENTS WITH HIGH RISK MYELODYSPLASTIC
SYNDROMES (HR-MDS) OR ACUTE MYELOID LEUKEMIA (AML), FOR WHOM TREATMENT WITH HYPOMETHYLATING
AGENTS (HMAS) IS INEFFECTIVE
    * PRIMARY ENDPOINT WAS MET AND INCLUDED OVERALL RESPONSE RATE (CR, CRI, PR OR SD) ASSESSED
AFTER 4
TREATMENT CYCLES

Source text for Eikon:  ID:nObi1qpGSa 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))